Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Receivables data on record, last reported at $366.7 million in Q4 2025.

  • For Q4 2025, Receivables rose 36.1% year-over-year to $366.7 million; the TTM value through Dec 2025 reached $366.7 million, up 36.1%, while the annual FY2025 figure was $366.7 million, 36.1% up from the prior year.
  • Receivables reached $366.7 million in Q4 2025 per APLS's latest filing, up from $352.1 million in the prior quarter.
  • Across five years, Receivables topped out at $366.7 million in Q4 2025 and bottomed at $719000.0 in Q2 2021.
  • Average Receivables over 5 years is $152.0 million, with a median of $172.0 million recorded in 2023.
  • Peak YoY movement for Receivables: skyrocketed 2184.37% in 2023, then fell 28.75% in 2025.
  • A 5-year view of Receivables shows it stood at $10.1 million in 2021, then dropped by 9.24% to $9.2 million in 2022, then surged by 2184.37% to $209.5 million in 2023, then rose by 28.64% to $269.5 million in 2024, then soared by 36.1% to $366.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $366.7 million in Q4 2025, $352.1 million in Q3 2025, and $220.1 million in Q2 2025.